Ipsen
Ipsen Licenses Day One's Ojemda Outside US in Deal Worth $461M
Ojemda was approved in the US earlier this year as a treatment for BRAF-altered pediatric low-grade glioma.
Ipsen Acquires Epizyme, Garners Tazverik, Other Oncology Assets
The transaction, slated to close in Q3, will give Ipsen the EZH2 inhibitor, a SETD2 inhibitor, and other preclinical programs involving epigenetic targets.